NOV 02, 2016 12:00 PM PDT

Immunoassays and Pain Management Drug Testing

Speaker
  • Director; Siemens Healthineers
    Biography
      Nihmat Morjana, Ph.D., M.Sc. is a Director at Siemens Healthineers. Dr. Morjana received his Ph.D. in Biochemistry, from Queen's University working on the structure/mechanism and drug interaction of Aldo-Keto Reductases. Following his post-doctoral training at Baylor College of Medicine, he joined Baxter/Dade International/Dade Behring/Siemens. He led projects on the development and commercialization of drugs of abuse, pain management and immunosuppressant immunoassays. Dr. Morjana has 24 years of experience in the diagnostic industry. His current work focus includes immunoassay and application development on multiple-instruments. He is a member of ASBMB, SOFT and AACC and has published peer reviewed papers and abstracts and an inventor on patents. He is on the Editorial Board of Biotechnology and applied Biochemistry and served on the Editorial board of the Internet Journal of Genomics and Proteomics.

    Abstract

    In the past several years, there has been an increase in drug testing associated with chronic pain. Immunoassays are the most common method for initial screening which can test for a specific drug, metabolite, or a class of drugs.  The drug tests are used routinely in the workplace drug testing and periodic testing for drug compliance.  Commercially available immunoassays vary in their features, specificities, and screening thresholds.  Therefore, the results should be looked at with understanding of the immunoassay used in the testing and drug metabolism.  Immunoassays, which are designed for detection of the abuse of drugs, may be suitable for pain management testing.   Immunoassay low cutoff levels may provide laboratories with more sensitive methods for drug monitoring and in identifying abuse and misuse of prescription drugs.  This presentation will discuss immunoassay features, commercial drug tests for opioids/other drugs, and their suitability for pain management testing.
     


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources